Articles
| Open Access |
DOI: Features Of The Pathogenesis And Correction Of Anemia Induced By Antiviral Therapy For Hepatitis C
Ismatova Mekhriniso Nasritdinovna , Bukhara State Medical Institute, Uzbekistan Nurullaeva Dilnoza Fatullevna , Bukhara State Medical Institute, UzbekistanAbstract
HCV infection remains one of the leading problems in the diagnosis and treatment of chronic liver disease, given the scale of hepatitis C virus infection worldwide, the significant number of unexamined but at-risk patients, and the incidence of cirrhosis and liver cancer. Anemia is the most common hematological adverse event, which in turn significantly reduces the quality of life of patients during antiviral therapy, their adherence to treatment, and increases the risk of developing cardiovascular, renal and cerebral disorders.
Keywords
Anemia, hepatitis
References
Moiseev S.V., Abdurakhmanov D.T. How to improve the results of standard antiviral therapy in patients with chronic hepatitis C: the role of hematopoietic growth factors. Clinical Pharmacology and Therapy, 2011, 20 (2), P.2 [in russian]
Sulkowski M et al. EASL 2008. Abstract 991, Oral Presentation. [in russian]
Bakulin I.G., Sandler Yu.G., Sharabanov A.S. Hematological adverse events during antiviral therapy in patients with chronic hepatitis C. Hepatological Forum, 2011, 4, C.2 [in russian]
Kwo PY, Lawitz EJ, McCone J, et al. S-Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376: 705–16.
Berman K, Kwo PY. Boceprevir, an NS3 protease inhibitor of HCV. Clin Liver Dis 2009; 13: 429–39.
Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195–206.
Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previ- ously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405–16.
www.anemia.ru
Sulkowski M.S., Shiffman M.L., Afdhal N.H. et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology, 2010,139, 1602-16011
McHutchinson J., Lawitz E., Shiffman M.L. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med., 2009, 361, 580-593.
Sakamoto N., Tanaka Y. et al. ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese pa- tients with chronic hepatitis C. Hepatology Research, 2010, 40, 1063-1071/
Hitomi Y., Cirulli E.T., Fellay J. et al. Inosine tripfosphate protects against ribavirin-induced ATP loss by restoring adenylosuccinate synthase function. Gastroenterology, 2011, 140, 1314-1321.
Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-asso- ciated anemia. Jama 2008, 299, 914-924.
Article Statistics
Copyright License
Copyright (c) 2021 The American Journal of Medical Sciences and Pharmaceutical Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.